Myeloma News and Research

RSS

Some immune cells are smarter than others killing more cancer

In efforts to educate the body to fight off cancer, researchers have found that some immune cells are "smarter" than others. Working with collections of human cells, Johns Hopkins Kimmel Cancer Center scientists tested kill-rates of two kinds of T-cells "primed" to home in on myeloma, a cancer of the bone marrow. Those that live in the bone marrow outperformed their counterparts circulating in the blood by more than 90 percent.

1 Mar 2005

Association noted between certain non-lver cancers and hepatitis C

People infected with the hepatitis C virus (HCV) have a higher risk of developing non-Hodgkin's lymphoma and multiple myeloma, according to a recent study of the Swedish population.

22 Feb 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Link found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw

Doctors at Long Island Jewish (LIJ) Medical Center recently discovered a link between a common chemotherapy drug and a serious bone disease called osteonecrosis of the jaw (ONJ).

13 Dec 2004

Thiazolidinedione (TZD) class of anti-diabetic drugs may be a potential targeted therapy for myeloma patients

In laboratory tests on multiple myeloma cells, University of Rochester researchers found that this type of cancer expresses a protein that makes it an easy target for an existing class of diabetes drugs. After more investigation, they hope the discovery will lead to a new, targeted therapy for myeloma patients.

8 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004

Combination of thalidomide and dexamethasone may be a promising treatment for multiple myeloma

The combination of two pills -- thalidomide and dexamethasone -- may be an effective alternative to the intravenous chemotherapy commonly prescribed to patients with multiple myeloma, according to a large collaborative study conducted by the Eastern Cooperative Oncology Group and led by a Mayo Clinic investigator.

7 Dec 2004

Thalidomide shows promise in fighting myeloma

Thalidomide, a drug often used to treat symptoms of leprosy and in testing to fight HIV, is now demonstrating activity in fighting a common cancer that occurs in bone marrow, myeloma.

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Phase 3 results of Genasense plus Dexamethasone in patients with advanced multiple myeloma

Genta Incorporated announced that results from the Company's randomized Phase 3 clinical trial of Genasense(R) (oblimersen sodium) Injection in patients with relapsed or refractory multiple myeloma were presented today at the annual meeting of the American Society of Hematology (ASH) in San Diego, CA.

4 Dec 2004

Botox reduces pain and spasms during breast reconstruction after mastectomy

Botox, known for reducing wrinkles, also can be used to reduce pain and spasms during breast reconstruction after mastectomy, according to results of a recent University of Arkansas for Medical Sciences (UAMS) study.

29 Nov 2004

Scientists join forces to improve the effectiveness of a drug used to treat chronic myeloid leukaemia

Scientists from Glasgow and Liverpool are joining forces to improve the effectiveness of a drug used to treat a form of leukaemia, chronic myeloid leukaemia (CML), which affects 750 people in the UK each year.

24 Nov 2004

Cyclooxygenase (COX) inhibitors tested in both prevention and treatment clinical trials

Numerous compounds are examined by the National Cancer Institute (NCI) for their potential to prevent or treat cancer. One class of compounds, cyclooxygenase (COX) inhibitors, is currently being tested in both prevention and treatment clinical trials.

4 Nov 2004